THCA Therapeutics has completed Version 3.1 of its THCA PURE™ Oral Technical Disclosure & Intellectual Property Assessment following a targeted review of representative prior art.

The assessment sharpened the company’s IP strategy by distinguishing the known broader nested-capsule landscape from potential THCA-specific opportunities that may emerge through formulation definition, controlled processing, measurable product performance, packaging and comparative development data.

The work provides a more disciplined framework for future prototype development, experimental design and patent-counsel review.

No patent application, patent-pending status or freedom-to-operate conclusion is currently asserted.